AtriCure (ATRC) Set to Announce Earnings on Thursday

AtriCure (NASDAQ:ATRCGet Free Report) is scheduled to announce its earnings results after the market closes on Thursday, February 15th. Analysts expect the company to announce earnings of ($0.22) per share for the quarter. Investors that are interested in registering for the company’s conference call can do so using this link.

AtriCure Price Performance

Shares of AtriCure stock opened at $33.52 on Tuesday. AtriCure has a one year low of $30.74 and a one year high of $59.61. The stock’s fifty day moving average is $34.51 and its 200 day moving average is $39.94. The stock has a market cap of $1.59 billion, a P/E ratio of -62.28 and a beta of 1.40. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.31 and a current ratio of 3.06.

Institutional Trading of AtriCure

Several large investors have recently added to or reduced their stakes in the company. MML Investors Services LLC boosted its stake in shares of AtriCure by 10.5% in the first quarter. MML Investors Services LLC now owns 5,216 shares of the medical device company’s stock worth $216,000 after buying an additional 497 shares during the last quarter. Creative Planning purchased a new stake in shares of AtriCure in the third quarter worth about $203,000. Citigroup Inc. boosted its stake in shares of AtriCure by 36.6% in the first quarter. Citigroup Inc. now owns 4,782 shares of the medical device company’s stock worth $198,000 after buying an additional 1,282 shares during the last quarter. Lazard Asset Management LLC boosted its stake in shares of AtriCure by 94.4% in the third quarter. Lazard Asset Management LLC now owns 3,534 shares of the medical device company’s stock worth $154,000 after buying an additional 1,716 shares during the last quarter. Finally, Tower Research Capital LLC TRC boosted its stake in shares of AtriCure by 112.0% in the second quarter. Tower Research Capital LLC TRC now owns 3,042 shares of the medical device company’s stock worth $150,000 after buying an additional 1,607 shares during the last quarter. Hedge funds and other institutional investors own 94.30% of the company’s stock.

Analyst Upgrades and Downgrades

ATRC has been the topic of a number of recent analyst reports. StockNews.com raised AtriCure from a “sell” rating to a “hold” rating in a report on Thursday, November 9th. Needham & Company LLC decreased their price target on AtriCure from $49.00 to $44.00 and set a “buy” rating on the stock in a report on Thursday, January 4th. JPMorgan Chase & Co. cut their price objective on AtriCure from $60.00 to $50.00 and set an “overweight” rating for the company in a research report on Thursday, November 2nd. Finally, JMP Securities restated a “market outperform” rating and set a $60.00 price objective on shares of AtriCure in a research report on Wednesday, November 29th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $59.50.

Read Our Latest Analysis on AtriCure

AtriCure Company Profile

(Get Free Report)

AtriCure, Inc develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation.

Read More

Earnings History for AtriCure (NASDAQ:ATRC)

Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.